此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Clinical Trial of HG146 Administered to Participants With Adenoid Cystic Carcinoma (HG146)

2026年9月16日 更新者:HitGen Inc.

A Phase Il Clinical Study to Evaluate the Efficacy and Safety of HG146 Capsules in Participants With Recurrent or Metastatic Adenoid Cystic Carcinoma.

This is a Phase II, open-label, non-randomized, multicenter study to evaluate the clinical efficacy and safety of HG146 in participants with recurrent or metastatic adenoid cystic carcinoma. This study is divided into two stages. 40 participants will be enrolled in the first stage. The efficacy and safty data will apply to make go or no go decision. Then the second stage will continue to enroll 100 Particapants.

研究概览

地位

招聘中

干预/治疗

研究类型

介入性

注册 (估计的)

140

阶段

  • 阶段2

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

学习地点

    • Shanghai Municipality
      • Shanghai、Shanghai Municipality、中国、200000
        • 招聘中
        • Shanghai Oriental Hospital
        • 接触:

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Signed informed consent form (ICF) and able to comply with study.
  • Age ≥18 years, gender unlimited.
  • Recurrent or metastatic adenoid cystic carcinoma with evidence of disease progression (imaging progression or clinical evidence of progression) within one year of histological or cytological diagnosis.
  • Estimated survival >12 weeks, as determined by the investigator.
  • The United States Eastern Cancer Consortium (ECOG) physical status score 0-1.
  • Has adequate organ function.
  • At least 1 measurable tumor lesion according to RECISTv1.1 criteria.

Exclusion Criteria:

  • Symptomatic central nervous system (CNS) metastases that have required steroids within 4 weeks prior to first dose of study treatment.
  • Received prior therapies targeting HDAC.
  • Chemotherapy was received within 21 days before the first administration of the study treatment, and anti-tumor therapy such as radiotherapy, biotherapy, targeted therapy, and immunotherapy was received within 28 days before the first administration of the study treatment [small molecule targeted drugs, Chinese medicines with anti-tumor indications, and local palliative radiotherapy were 14 times before the first administration of the study drug.
  • Used strong CYP3A4 inhibitors or inducers within 7 days before the first use of the investigational drug.
  • Major surgery or major injury <=28 days before the first dose of study treatment,or anticipated major surgery during the study.
  • Prior allogeneic bone marrow transplantation or other solid organ transplantation
  • Active infection requiring systemic treatment.
  • Current or past presence of other malignancies (other than adequately treated basal cell or squamous cell carcinoma of the skin and carcinoma in situ of the cervix), unless radical treatment has been performed and there is no evidence of recurrence and metastasis in the last 5 years.
  • A person is known to be allergic to any active ingredient or excipient of the investigational drug.
  • Pregnant or lactating women.
  • patients with drug abuse or chronic alcohol abuse that may affect the evaluation of the test results.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:不适用
  • 介入模型:单组作业
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:Clinical Trial of HG146 Administered to participants with Adenoid cystic carcinoma

Experimental: HG146 Monotherapy Arm Description: Participants will receive HG146 per os at every two days intervals (qod) for 14 consecutive days,7 days off, 21 days/ cycle.

HG146 is available as Capsule at a unit dose strength of 5 mg and 10 mg.

其他名称:
  • HG146胶囊

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
objective response rate (ORR)
大体时间:From enrollment to the end of treatment at 4 weeks

ORR will be assessed by the investigators using RECIST v1.1

From enrollment to the end of treatment at 4 weeks
6 Months Progression-Free Survival (PFS)
大体时间:From enrollment to treatment at 6 months.

PFS will be assessed by the investigators using RECIST v. 1.1

From enrollment to treatment at 6 months.

次要结果测量

结果测量
措施说明
大体时间
Progression-Free Survival (PFS)
大体时间:From enrollment to treatment at 12 months

PFS will be assessed by the investigators using RECIST v1.1

From enrollment to treatment at 12 months
Duration of response (DoR)
大体时间:From enrollment to the end of treatment at 4 weeks

DOR will be assessed by the investigators using RECIST v1.1

From enrollment to the end of treatment at 4 weeks
Disease control rate (DCR)
大体时间:From enrollment to the end of treatment at 4 weeks

DCR will be assessed by the investigators using RECIST v1.1

From enrollment to the end of treatment at 4 weeks
Overall survival (OS)
大体时间:From enrollment to the end of treatment at 4 weeks

OS will be assessed by the investigators

From enrollment to the end of treatment at 4 weeks
Time-to-response (TTR)
大体时间:From enrollment to the end of treatment at 4 weeks

TTR will be assessed by the investigators using RECIST v1.1

From enrollment to the end of treatment at 4 weeks
Population pharmacokinetics (PopPK)
大体时间:From Cycle1 Day7 to Day13, 21 days per cycle

PopPK will be detected to predict exposure level of HG146 in human body.

From Cycle1 Day7 to Day13, 21 days per cycle

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

赞助

调查人员

  • 首席研究员:Ye Guo、Shanghai Oriental Hospital

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2024年12月13日

初级完成 (估计的)

2028年12月31日

研究完成 (估计的)

2029年6月30日

研究注册日期

首次提交

2025年1月6日

首先提交符合 QC 标准的

2025年1月13日

首次发布 (实际的)

2025年1月17日

研究记录更新

最后更新发布 (实际的)

2026年9月21日

上次提交的符合 QC 标准的更新

2026年9月16日

最后验证

2026年9月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅